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Regional Anesthesia and Breast Cancer Recurrence 
Abstract 
Breast cancer is the most common type of cancer in women in the United States, and 
surgical resection is the definitive treatment.  However, cancer recurrence and metastasis remains 
a concern for the lifetime of the patients affected.  Therefore, much interest has been focused on 
how anesthetic technique may impact the rates of cancer recurrence and metastasis following 
breast cancer surgery.  In this review, the potential for regional analgesia to reduce the 
recurrence rate of breast cancer post-operatively is discussed.  Supporting evidence from 
multiple studies is presented, along with a discussion of potential areas of future research that is 
needed.  At this time, there is no definitive answer regarding the optimal anesthetic technique to 
enhance patient outcomes after breast cancer surgery.  However, ongoing research has the 
potential to enhance our understanding of how anesthetic technique may impact long-term breast 
cancer survival. 
Introduction 
In the field of anesthesia, practitioners are primarily concerned with the immediacy of 
their actions in the delivery of a safe and successful anesthetic.  Anesthetic choice predominantly 
focuses on adequate sedation for the surgical procedure, perioperative pain control, respiratory 
and hemodynamic stability, as well as prevention of nausea and vomiting.  When the patient’s 
condition changes during the anesthetic, interventions are made to rapidly address those changes 
without much consideration for the potential long-term impacts of those interventions.  Long-
term effects of anesthetic choice on patient morbidity and mortality, which may not manifest for 
many years, are rarely considered in anesthetic plans, if at all.  However, one area where 
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anesthetic choice may have a significant influence on long-term morbidity and mortality is the 
field of surgical oncology.   
Perioperatively, several significant factors have been identified as having potential 
influence on cancer recurrence post-operatively, including physical manipulation of the tumor, 
immune system health of the patient, the stress response caused by the surgical intervention, and 
the choice of anesthetic technique (Snyder & Greenberg, 2010).  For anesthetists, there has been 
a great deal of interest in the effects anesthetic technique may have on the recurrence rate of 
cancer after surgical tumor resection (Snyder & Greenberg, 2010).  Of particular interest is the 
influence regional anesthesia may have on the long-term morbidity and mortality of patients 
undergoing surgical intervention for cancer treatment.  
Anesthetic technique has been identified as having influence over immunosuppression, 
stress response, as well as tumor cell activity (Snyder & Greenberg, 2010).  In the review by 
Snyder & Greenberg (2010) it was noted that all anesthetics (intravenous and inhalation) have 
the potential to decrease the immune response of the patient by inhibiting natural killer (NK) cell 
activity (Snyder & Greenberg, 2010).  NK cells are noted as being one of the primary immune 
response cells in the control of cancer cells, which can often be released into circulation after 
tumor manipulation during surgery, leading to metastasis (Snyder & Greenberg, 2010).  The 
stress response of acute surgical pain has also been identified as a causative factor in reducing 
NK cell activity and enhancing cancer cell proliferation intra-operatively (Snyder & Greenberg, 
2010).  Unfortunately, the use of opioids to treat acute pain has been implicated as a causative 
factor in suppressing NK cell activity (Snyder & Greenberg, 2010).  Therefore, regional 
anesthesia and analgesia has been identified as a potential beneficial therapy to maintain immune 
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function during surgical resection of tumors, with the potential benefit of decreasing the risk of 
cancer recurrence and metastasis (Snyder & Greenberg, 2010).   
In this literature review, evidence will be presented to illustrate the potential regional 
anesthesia may have on long-term morbidity and mortality in breast cancer patients who undergo 
surgical excision of their primary cancer.  Specifically, the following question will be addressed; 
in patients undergoing mastectomies for treatment of breast cancer, how does regional 
anesthesia/analgesia compare to inhalation anesthesia with opioid analgesia in the post-operative 
recurrence rate of breast cancer?  In addition, a discussion will be offered to illustrate why 
anesthetists should be open to plan their anesthetic choice in order to optimize the recovery 
potential in breast cancer patient.  
Literature Review 
Studies selected for inclusion in this review were found using the PubMed database with 
search terms of “cancer, regional anesthesia, epidural, paravertebral, breast cancer, recurrence, 
and metastasis”.  Unfortunately, there were few articles of sufficient quality that directly applied 
to the treatment of breast cancer patients.  Therefore, additional articles were selected that were 
similar in nature to the focus of this review.  These articles were felt to lend support to the 
overall premise that there exists a potential benefit in the use of regional anesthesia in reducing 
cancer recurrence rates in breast cancer patients. 
To date, there was only one study that closely addressed the question posed for this 
literature review (Exadaktylos, Buggy, Moriarty, Mascha, & Sessler, 2006).  In this retrospective 
study, the effects of regional anesthesia and analgesia were examined to determine its influence 
on breast cancer recurrence and metastasis post-operatively (Exadaktylos et al., 2006).  A total of 
129 cases were examined from one hospital where patients underwent mastectomy with axillary 
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clearance for primary breast cancer treatment (Exadaktylos et al., 2006).  All study participants 
received inhalation anesthesia for their procedures (Exadaktylos et al., 2006).  The treatment 
groups consisted of 50 patients receiving regional analgesia (continuous paravertebral blockade), 
and 79 patients receiving opioid analgesia (Exadaktylos et al., 2006).  The primary outcomes 
measured in the study were primary breast cancer recurrence and/or metastasis over 2-4 years 
post-operatively (Exadaktylos et al., 2006).  Results from this study indicate a significant 
decrease in cancer recurrence or metastasis in those patients receiving regional analgesia 
compared to the opioid analgesia group (Exadaktylos et al., 2006).  This pattern was evident at 
both 24 and 36 months follow-up (Exadaktylos et al., 2006).   
While the results from this study were significant, the study design does raise some 
concerns in its interpretation.  The study is a retrospective design, so the authors had no control 
over the patient selection criteria, or the specific anesthetic techniques utilized in the study.  In 
addition, as the sample size was relatively small there is an increased chance that an effect was 
detected when one may not actually exist (Trochim & Donnelly, 2008).  Also, the external 
validity of the results must be questioned, as the study was conducted at one facility and results 
may not be reflected by the larger population (Trochim & Donnelly, 2008).  However, even with 
these concerns in mind the results from this study indicate a positive relationship between 
regional analgesia and improved patient outcomes in the surgical treatment of breast cancer. 
Further evidence into the potential benefit of regional anesthesia in the treatment of 
breast cancer comes from the study of anesthetic technique on breast cancer cell activity in vitro.  
In one in vitro study, breast cancer cells were exposed to serum collected from patients 
undergoing mastectomy for breast cancer treatment (Deegan et al., 2009).  Patients within the 
study were randomized into two treatment groups, those receiving paravertebral blockade with 
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Propofol anesthetic and those receiving opioid analgesia with Sevoflurane anesthetic (Deegan et 
al., 2009).  The primary outcomes measured in this study were the extent of breast cancer cell 
proliferation, and the extent of cancer cell migration through a culture medium (Deegan et al., 
2009).  As an in vitro study, the goal was to determine how anesthetic technique might affect the 
ability of breast cancer cells to spread during surgical resection of a primary tumor, leading to 
recurrence or metastasis later in life (Deegan et al., 2009).   
A total of 22 patients were recruited for the study, and were randomly assigned to the 
treatment groups (11 in each group) (Deegan et al., 2009).  Serum was collected from study 
participants pre-operatively and 24 hours post-operatively (Deegan et al., 2009).  Cultured breast 
cancer cells were exposed to the collected serum, allowed to culture for 24-48 hours, and then 
assessed for proliferation and migration (Deegan et al., 2009).  Results from the analysis indicate 
that breast cancer cell proliferation was decreased in those patients receiving paravertebral 
blockade with Propofol compared to those receiving opioids with Sevoflurane (Deegan et al., 
2009).  The authors note there was no significant change in breast cancer cell migration between 
the two groups (Deegan et al., 2009).   
Although this study had a small sample size, the overall design was robust in answering 
the questions posed by the authors.  There was homogeneity between the two treatment groups, 
and the analysis of the results was clear and presented well.  Although this was an in vitro study, 
it lends support to the idea that regional analgesia with Propofol anesthesia has the potential to 
decrease breast cancer recurrence or metastasis after surgical resection of breast cancer tumors 
by inhibiting cancer cell proliferation. 
Another in vitro study examined the rate of apoptosis in cultured breast cancer cells when 
exposed to serum from patients undergoing mastectomy (Jaura, Flood, Gallagher, & Buggy, 
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2014).  Serum was collected from 20 study participants (10 per group) who were given one of 
two anesthesia options for their surgical procedure.  One group was given paravertebral blockade 
and Propofol anesthesia and the second group was given Sevoflurane anesthesia with morphine 
analgesia (Jaura et al., 2014).  Serum was collected pre- and post-operatively, and cultured breast 
cancer cells were exposed to the subjects’ serum, after which the extent of cancer cell apoptosis 
was measured (Jaura et al., 2014). 
Results from the study demonstrated a higher rate of cancer cell apoptosis in the cultures 
exposed to serum from patients who received regional analgesia with Propofol anesthesia (Jaura 
et al., 2014).  These results indicate that factors responsible for breast cancer cell elimination 
may be inhibited during surgery when Sevoflurane anesthesia with morphine analgesia is utilized 
(Jaura et al., 2014).  Although these results are supportive for the use of regional analgesia with 
Propofol to reduce cancer recurrence in breast cancer surgery, it is clear this is a small in vitro 
study and extrapolation of these results to clinically relevant treatment choices must be viewed 
with caution. 
A third in vitro study utilizing the same protocol as described above examined the effects 
of serum from patients undergoing mastectomy for resection of primary breast cancer on 
cultured NK cell activity (Buckley, McQuaid, Johnson, & Buggy, 2014).  As noted above, NK 
cell activity is thought to be important in the elimination of cancer cells in vivo (Snyder & 
Greenberg, 2010).  The two study groups were the same as above, paravertebral block with 
Propofol and Sevoflurane with morphine (Buckley et al., 2014).  Cultured NK cells were 
exposed to serum from the study participants, and then monitored for cytotoxicity towards 
cultured cancer cells (Buckley et al., 2014). 
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Results from the study indicate that those patients exposed to Sevoflurane and morphine 
had impaired cytotoxicity of cultured NK cells towards cultured breast cancer cells (Buckley et 
al., 2014).  The authors note that this result would seem to indicate a potential benefit in the use 
of paravertebral analgesia with Propofol anesthesia by maintaining NK cell activity (Buckley et 
al., 2014).  In maintaining NK cell activity there is a potential to decrease the chances of breast 
cancer spread after mastectomy (Buckley et al., 2014).  However, the authors also note that this 
is a small-scale pilot study with in vitro sampling, which should be viewed with caution when 
trying to extrapolate clinically relevant treatment choices (Buckley et al., 2014).  Although the 
study is small scale, the design is robust in answering the question posed by the authors, and its 
results should be viewed as providing support to the use of regional analgesia in improving 
patient outcomes in the surgical treatment of breast cancer. 
As there is a paucity of research articles directly addressing the question posed for this 
literature review, supporting evidence was sought for the use of regional anesthesia in reducing 
post-operative morbidity and mortality in the treatment of cancer.  A retrospective meta-analysis 
was conducted by Weng et al. (2016) in an effort to exam the effects of neuraxial anesthesia, 
including epidural or spinal anesthesia, on morbidity and mortality following cancer surgery.  
After identifying 318 studies initially eligible for inclusion, 21 studies were ultimately selected 
for analysis (Weng et al., 2016).  The goals of the meta-analysis were to examine the effects of 
neuraxial anesthesia, with or without general anesthesia, on the overall survival and recurrence 
free survival of patients after cancer surgery (Weng et al., 2016).  The authors included studies 
published from 2004 to 2014, incorporating multiple different cancer types (Weng et al., 2016).  
Of these studies, 15 examined overall survival and 19 examined recurrence free survival (Weng 
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et al., 2016).  Several studies selected for the meta-anlysis examined both overall and recurrence 
free survival, so were included in the analysis of each (Weng et al., 2016).   
Results from the meta-analysis indicate a positive effect of neuraxial anesthesia on both 
overall survival, and recurrence free survival after cancer surgery when compared with general 
anesthesia alone (Weng et al., 2016).  In addition, the authors noted that the positive influence of 
neuraxial anesthesia was significant even though the studies examined included multiple 
different cancer types (Weng et al., 2016).  In an attempt to determine if specific cancers had an 
influence on the results identified by the primary analysis, the authors examined the influence of 
the types of cancers found more frequently in their literature search.   
The effect of neuraxial technique on overall survival was analyzed in colorectal cancer (5 
studies) and prostate cancer (3 studies) (Weng et al., 2016).  In this sub-analysis there was a 
significant effect of neuraxial technique in colorectal cancers, but not in prostate cancer (Weng et 
al., 2016).  The lack of significance in prostate cancer may have been due to the small number of 
studies used in the analysis.  In comparison, the effect of neuraxial technique on recurrence free 
survival was analyzed in prostate cancer (7 cases) and ovarian cancer (3 cases) (Weng et al., 
2016).  In this analysis there was no significant effect of neuraxial technique on the recurrence of 
cancer in either group (Weng et al., 2016).  The authors indicate that the strongest influence of 
neuraxial technique on cancer surgery is overall survival, but also note that there seems to be 
support for its use in decreasing cancer recurrence (Weng et al., 2016). 
Overall, the study by Weng et al. (2016) provides strong support for the use of neuraxial 
anesthesia in the surgical treatment of cancer.  Limitations of this analysis include a wide variety 
of cancer types examined to address the questions posed by the authors.  A more robust analysis 
might include more studies with one specific cancer type.  However, because of the limited 
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number of studies available, such an analysis was not possible.  Interestingly, the authors’ use of 
many different cancer types in this analysis lends support to the idea that there is a positive effect 
of neuraxial anesthesia on cancer surgery outcomes.  Another weakness of the study was the lack 
of experimental design control inherent to retrospective analysis.  The study by Weng et al. 
(2016) only examines the effects of presence or absence of neuraxial anesthesia during cancer 
surgery on their identified outcomes.  It does not examine the influence of other variables such as 
inhalation anesthetics, opioids, and inflammation that may enhance the propensity for cancer 
recurrence or overall mortality.  These uncontrolled for variables may confound a positive effect 
from neuraxial anesthesia, decreasing the authors’ ability to detect a significant effect in their 
analysis.  This is a common problem in retrospective studies, as the authors have no control over 
the study design of previous works.  However, even with these limitations, the meta-analysis 
indicates a positive effect of neuraxial anesthesia in these cancer cases. 
A closer examination of the studies utilized by Weng et al. (2016) can help to elucidate 
the potential impact neuraxial anesthesia may have on cancer surgery outcomes.  One of the 
studies used by Weng et al. (2016) investigated the effects of epidural analgesia, compared to 
traditional analgesia, on overall and recurrent free survival of patients undergoing colectomy for 
colorectal cancer (Cummings, Xu, Cummings, & Cooper, 2012).  The study was a retrospective 
population based cohort study, where cases within a large Medicare database were identified and 
selected based on a series of inclusion criteria (Cummings et al., 2012).  The selection criteria 
was robust and identified over 40,000 cases that fulfilled their selection criteria, with more than 
9,000 of those having an epidural at the time of surgery (Cummings et al., 2012).   
Significant findings from the analysis of these cases indicated an increase in 5 year 
overall survival for those patients who received an epidural at the time of their surgery compared 
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to those who did not (Cummings et al., 2012).  The authors do note that there was a difference in 
the population composition between the different study groups.  Those patients receiving 
epidurals were slightly younger with lower comorbidity scores compared to the non-epidural 
group (Cummings et al., 2012).  In addition, the epidural group had a higher likelihood to be 
white, males, married, and located in the Midwest region of the country (Cummings et al., 2012).  
After adjusting for patient characteristics, the analysis of the study continued to indicate an 
increased survival in the epidural use group (Cummings et al., 2012).  In contrast to an increase 
in overall survival, there was no difference noted in the rates of colorectal cancer recurrence 
between the two groups studied (Cummings et al., 2012).   
This study provides support in the use of epidural analgesia/anesthesia in reducing overall 
mortality in colorectal cancers.  It utilized a robust database with a large sample size, and had a 
well designed inclusion/exclusion criteria.  It was confounded somewhat in the differences noted 
in the two study groups identified (see above) and this does raise some doubts about the strength 
of the study conclusion.  In addition, although the authors were able to utilize information from a 
large population database, they were limited in their lack of control over study design.  The 
authors admit there may have been unintended bias in patient selection, or unaccounted for 
cofounding factors that may have influenced the results of the study (Cummings et al., 2012). 
Another study utilized by Weng et al. (2016) examined the effect of neuraxial analgesia, 
as compared to opioid analgesia, on cancer recurrence in patients undergoing surgical resection 
of prostate cancer (Biki et al., 2008).  In their retrospective analysis medical records were 
obtained from one facility where patients underwent radical prostatectomies (Biki et al., 2008).  
All patients received general anesthesia for their procedures, with patient selection based on the 
presence or absence of epidural placement for these procedures (Biki et al., 2008).  A total of 225 
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cases were selected for analysis, with 102 of those cases receiving epidurals (Biki et al., 2008).  
Patients not receiving epidurals were given opioid analgesia post-operatively (Biki et al., 2008).  
The primary outcome measured in this analysis was recurrence of prostate cancer, based upon an 
elevation of prostate-specific antigen (Biki et al., 2008).  
Results from the analysis indicate that recurrence-free survival was higher in those 
patients that received epidural analgesia when compared to those receiving opioid analgesia 
(Biki et al., 2008).  Interestingly, the two study groups were not homogenous in their make-up, 
with the epidural group tending to have more complications, more comorbidities, and shorter 
surgeries (Biki et al., 2008).  Despite the tendency to be sicker and have more surgical 
complications, the epidural group still demonstrated a 57% lower risk of cancer recurrence 
compared to the opioid group (Biki et al., 2008).   
The results from this study further support the use of neuraxial analgesia in decreasing 
cancer recurrence in patients undergoing surgical resection of cancerous tumors.  However, the 
sample size is relatively small (225 total cases), and the study only included cases from one 
facility (Biki et al., 2008).  This study design may exhibit a decrease in external validity, and 
therefore may not provide results that are transferrable to different populations (Trochim & 
Donnelly, 2008).  However, the results are promising and indicate a need for more robust testing 
of the efficacy of neuraxial analgesia in the reduction of cancer recurrence. 
In addition to the use of regional techniques, other factors associated with anesthetic 
techniques and the recurrence rates of breast cancer have been explored in the literature.  One 
study examined the influence of Propofol based anesthesia compared to Sevoflurane anesthesia 
on recurrence and overall survival of patients undergoing mastectomy for breast cancer (Lee, 
Kang, Kim, Kim, & Kim, 2016).  In this retrospective study 325 cases were identified from one 
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treatment center where patients underwent mastectomy for breast cancer treatment (Lee et al., 
2016).  Cases were selected over a 24-month period, and categorized into the Propofol anesthetic 
group (173 cases) or the Sevoflurane anesthetic group (152 cases) (Lee et al., 2016).  As it was a 
retrospective analysis, there was no control over adjunct medications given within those two 
groups (Lee et al., 2016).  The primary outcomes measured in the study were recurrence free 
survival and overall survival within 5 years of follow-up (Lee et al., 2016).   
Results from the study indicate there was no difference in overall survival within 5 years 
of mastectomy based on the anesthetic technique (Lee et al., 2016).   However, cancer recurrence 
within 5 years of mastectomy was greater in the group that received Sevoflurane compared to 
those patients that received Propofol as their anesthetic (Lee et al., 2016).   Results from this 
retrospective analysis seem to indicate a negative impact of Sevoflurane on recurrence free 
survival after surgical treatment for primary breast cancer. 
Although a significant difference was noted between treatment groups, the results from 
this retrospective study must be viewed with caution.  As the study participants were all selected 
from one facility the external validity of the results can be questioned (Trochim & Donnelly, 
2008).  In addition, as a retrospective study the authors had no control over the anesthetic 
technique utilized in their study groups.  Therefore, confounding factors may have influenced the 
results of their analysis.  An example of this was evident in the Propofol group, which showed 
higher usage of the opioid Remifentanil compared to the Sevoflurane group (Lee et al., 2016).  It 
is not clear how Remifentanil might have influenced the recurrence rate of breast cancer, if at all.   
Another study tried to determine the influence of intraoperative analgesics on the 
recurrence rates of breast cancer after mastectomy (Forget et al., 2010).  In this retrospective 
analysis, the authors examined the use of sufentanil, ketamine, clonidine, and ketorolac on breast 
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cancer recurrence (Forget et al., 2010).  There were 327 mastectomy cases identified from one 
facility, over a 5-year period, which were used for the analysis (Forget et al., 2010).  There was 
no specific treatment group identified, but cases were analyzed for cancer recurrence based upon 
different choices of analgesic use perioperatively (Forget et al., 2010).  Results from the analysis 
seem to indicate that those patients who received ketorolac before surgery had a lower rate of 
breast cancer recurrence compared to patients who did not receive ketorolac (Forget et al., 2010).   
While the results from this analysis are encouraging, the retrospective nature of the 
analysis makes generalizing the results difficult.  There was no control over the administration of 
analgesics in this study, and there are multiple factors that may confound the results found in this 
analysis.  The authors do note that patients who received ketorolac tended to be younger, but also 
show that correcting for age still showed a positive effect of ketorolac use in reducing cancer 
recurrence (Forget et al., 2010).  In addition to the retrospective nature of the study, the small 
sample size, and the use of one facility both act to reduce the external validity of the findings. 
Discussion 
The mechanisms that influence breast cancer occurrence, growth, and metastasis are 
complex, and vary from patient to patient (Snyder & Greenberg, 2010).  Breast cancer 
pathophysiology has been linked to genetic predisposition, exposure to environmental triggering 
agents, and immune system impairment (Snyder & Greenberg, 2010).  Because of this 
complexity, breast cancer recurrence after surgical resection remains a potential reality for 
patients long after surgical intervention to remove a primary tumor (Snyder & Greenberg, 2010).  
As members of the team of healthcare professionals involved in the care of breast cancer 
patients, anesthesia providers have a responsibility to provide a patient-centered anesthetic that 
will optimize patient outcomes postoperatively.  To this end, anesthetists must educate 
REGIONAL ANESTHESIA AND BREAST CANCER RECURRENCE 15 
themselves about the potential benefits of different anesthetic techniques for breast cancer 
anesthesia. 
From an anesthetists’ point of view, the primary concern is always to provide a safe and 
effective anesthetic that allows for the surgical procedure required to remove the breast cancer.  
Achieving that goal can be done is a variety of ways, and in these cases the anesthetic choice 
may have significant impact on the long-term survival of breast cancer patients.  Much of the 
debate regarding the ideal anesthetic revolves around limiting opioid use, and avoiding 
inhalation agents during breast cancer surgery as both of these agents have been implicated in 
higher recurrence rates of breast cancer postoperatively (Snyder & Greenberg, 2010).   
Snyder & Greenberg (2010) present evidence suggesting opioid use, both acutely during 
the surgical procedure and chronically postoperatively, can suppress the immune system of 
breast cancer patients.  This immune suppression is thought to allow for the proliferation of 
cancer cells that may be dislodged into circulation during surgical manipulation of the breast 
cancer tumor.  Therefore, the use of regional anesthesia for perioperative pain control could 
potentially avoid the immune system suppression, and potentially decrease breast cancer 
recurrence in these patients. 
Exadaktylos et al. (2006) were able to demonstrate the potential benefit of utilizing 
regional anesthesia in reducing breast cancer recurrence.  When compared to anesthetics relying 
on opioid analgesia, regional anesthesia using paravertebral blocks resulted in decreased rates of 
breast cancer recurrence and metastasis after surgical intervention (Exadaktylos et al., 2006).   
This retrospective study has been a hallmark in efforts to promote regional anesthesia in the 
reduction of breast cancer recurrence postoperatively.  However, as discussed above, the study 
has several limitations and does not address the influences of other factors present in the study, 
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such as the use of inhalation agents on cancer recurrence.  In addition, although the study 
focused on regional anesthetic technique for pain management, all of the patients involved in the 
study received some form of opioid perioperatively.  Therefore, it is not entirely clear if there 
would be an increased benefit in patient outcomes if an opioid-free anesthetic were to be utilized.  
Even with its limitations, the results from this study seem to indicate that there is a benefit to 
utilizing regional analgesia in reducing breast cancer recurrence, as compared to the use of 
opioids as the sole analgesia choice.   
Further evidence supporting the use of regional anesthesia for pain control, and avoiding 
inhalation agents for anesthesia comes from three in vitro studies.  These studies examined the 
effects of anesthetic technique on in vitro cancer cell proliferation and survival as a measure of 
the potential for breast cancer metastasis.  All of these studies had similar study designs, where 
two treatment groups were utilized; patients who received regional anesthesia combined with 
Propofol sedation, and patients who received opioid analgesia with Sevoflurane anesthesia.  In 
each study, cultured breast cancer cells were exposed to serum from the two treatment groups 
and the authors examined the effects based on the focus of their studies.   
Deegan et al. (2009) examined overall breast cancer cell proliferation when exposed to 
serum from the two groups.  The authors reported a decrease in breast cancer cell proliferation 
when cells were exposed to serum from patients receiving regional anesthesia combined with 
Propofol sedation (Deegan et al., 2009).  Conclusions from this study seem to indicate that 
cancer cell proliferation may be enhanced in the opioid/Sevoflurane group due to an inhibition of 
immune factors present in the serum from those study participants (Deegan et al., 2009).   
Jaura et al. (2014) examined rates of breast cancer cell apoptosis when exposed to serum 
from the two study groups.  Results from this study found that breast cancer cells had higher 
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rates of apoptosis when exposed to serum from patients who received regional analgesia with 
Propofol sedation (Jaura et al., 2014).  The authors implied that apoptosis was likely repressed in 
the opioid/Sevoflurane group through inhibition of serum mediated immune system factors.   
Buckley et al. (2014) examined the level of NK cytotoxicity towards breast cancer cells 
when exposed to serum from the two study groups.  Findings from this study described 
decreased levels of NK cell cytotoxicity towards breast cancer cells when exposed to serum from 
patients who received Sevoflurane with opioid analgesia (Buckley et al., 2014).  These results 
were attributed to a direct inhibition of NK cell immune activity in the opioid/Sevoflurane group 
(Buckley et al., 2014).   
Although these three reports were all in vitro studies, as a group they lend further support 
to the idea that regional anesthesia combined with Propofol sedation may maintain immune 
system efficacy in the control of cancer cell proliferation in vivo.  These studies act together to 
indicate that providing an anesthetic with opioids and Sevoflurane has an inhibitory effect on 
serum bound immune factors and NK cell activity.  This inhibitory tendency could allow for the 
proliferation of breast cancer cells during anesthesia for surgical resection of breast cancer.  
Therefore, the evidence indicates there is a potential for improved patient outcomes through the 
utilization of regional analgesia, combined with Propofol sedation in this patient population. 
The potential of regional anesthesia in producing improved patient outcomes after cancer 
surgery has been demonstrated by several studies.  Cummings et al. (2012) examined the effects 
of regional analgesia as compared to opioid analgesia in overall survival after colorectal cancer 
surgery.  This study was conducted independent of anesthetic agent employed.  Results from this 
study found an increase in overall survival postoperatively in those patients who received 
regional anesthesia as compared to those receiving opioid analgesia (Cummings et al., 2012).  
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Similarly, Biki et al. (2012) found that patients who received regional analgesia during surgical 
resection of prostate cancer had a decreased incidence of cancer recurrence postoperatively when 
compared to those who only received opioid analgesia, regardless of anesthesia agent use.  In 
addition, a meta-analysis by Weng et al. (2016) demonstrated that there was an increase in 
overall survival, and a decrease in cancer recurrence for patients who received regional 
anesthesia for multiple cancer types.  This benefit was present regardless of the type of anesthetic 
agent utilized, Propofol or inhalation agent (Weng et al., 2016). 
An obvious limitation of the studies discussed above is the lack of work focused 
specifically on determining the effects of anesthetic agents on breast cancer recurrence 
postoperatively.  Several of the studies reviewed above examined anesthetic technique, regional 
analgesia plus Propofol compared to opioid analgesia plus Sevoflurane, on patient outcomes.  
These analyses were not able to determine whether their findings were due to the anesthetic 
utilized or the type of analgesia selected.  However, one study was found that specifically 
focused on the choice of anesthetic agent and breast cancer patient outcomes (Lee et al., 2016).   
Lee et al. (2016) compared breast cancer recurrence and overall survival in patients who 
underwent anesthesia with Propofol anesthesia as compared to Sevoflurane anesthesia.  Both 
study groups received opioid analgesia, and no regional analgesia was utilized (Lee et al., 2016).  
Findings from the analysis showed no difference in overall survival between the two groups, but 
recurrence of breast cancer 5 years after surgical intervention was lower in patients who received 
Propofol anesthesia (Lee et al., 2016).  When these results are considered with the other studies 
listed above, the evidence becomes stronger that there is merit to the idea that limiting opioid 
use, utilizing regional analgesia, and avoiding Sevoflurane anesthesia has the potential to provide 
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for improved patient outcomes in patients undergoing surgical intervention for treatment of 
breast cancer.   
Unfortunately, the overall evidence to date is not conclusive regarding the ideal 
anesthetic that would provide for the best patient outcomes after breast cancer surgery.  Although 
there is supporting evidence for utilizing regional analgesia with Propofol sedation to reduce 
postoperative breast cancer recurrence, there is still much debate regarding the best practice in 
anesthetic management of these patients.  The studies discussed above have several limitations, 
including small sample sizes, and a high proportion of retrospective studies that were included in 
this analysis.  In addition, several of the studies were small in vitro experiments that may not be 
reflective of clinical outcomes.  Therefore, in order to provide definitive evidence to guide best 
practice anesthesia management in breast cancer surgery, a large scale, multi-center, prospective 
randomized control trial is needed.  Fortunately, one such trial is currently in progress (Sessler, 
Ben-Eliyahu, Mascha, Parat, & Buggy, 2008).   
The study currently under investigation by Sessler et al. (2008) is focused on determining 
the effects of anesthetic technique and pain management on postoperative breast cancer 
recurrence and overall survival.  This investigation is a robustly designed prospective 
randomized control study, conducted in several different medical facilities around the world 
(Sessler et al., 2008).  The research protocol clearly identifies inclusion and exclusion criteria for 
study participants, with a target of 1100 patients enrolled over the course of the investigation 
(Sessler et al., 2008).  The large sample size projected for the study affords an increased 
probability of avoiding a Type II error, and detecting a treatment effect if one exists (Trochim & 
Donnelly, 2008).  In addition, the inclusion of patients from multiple medical facilities provides 
for adequate external validity in the analysis of their results (Trochim & Donnelly, 2008).  
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Protocols are also identified for how anesthetic treatment groups are to be managed, which 
provides for consistency in the delivery of anesthetic technique for study participants.  The two 
treatment groups in the project are 1) regional analgesia using paravertebral blocks or thoracic 
epidurals combined with Propofol sedation, and 2) opioid analgesia combined with general 
anesthesia using Sevoflurane (Sessler et al., 2008).  The authors clearly identify two hypotheses 
being tested; 1) patients receiving regional analgesia combined with Propofol sedation will show 
a reduction in postoperative breast cancer recurrence, as compared to patients receiving opioid 
analgesia with Sevoflurane anesthesia, and 2) overall patient mortality will be reduced in the 
regional analgesia with Propofol sedation group as compared to the opioid analgesia with 
Sevoflurane group (Sessler et al., 2008).  It is hoped that once the results from this ongoing study 
are published, more clarity will be available for the optimal anesthetic technique in reducing 
postoperative morbidity and mortality for breast cancer patients. 
In conclusion, the selection of a patient-specific anesthesia plan is the primary 
responsibility of every anesthetist, and a multitude of factors go into the planning of a safe and 
effective anesthetic.  More often than not, anesthetists are concerned with the immediacy of their 
actions to address patient sedation, airway maintenance, and perioperative pain management.  It 
is much less common for anesthetists to consider how their anesthetic choices may influence 
long-term morbidity and mortality for the patients they care for.  As discussed in this review, the 
anesthetic management for patients undergoing surgical treatment for primary breast cancer may 
have lasting impacts on the cancer recurrence and overall survival of these patients.   
The evidence gathered in this review lends support to the idea that inhalation agents and 
opioid use during breast cancer surgery both have the potential to promote breast cancer 
recurrences many years after surgical intervention.  In comparison, evidence has been presented 
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indicating the potential for improved outcomes with the use of regional analgesia and Propofol 
sedation for patients undergoing surgical treatment of breast cancer.  While the evidence is not 
definitive, and we are still awaiting results from more robust investigations, there is an argument 
to be made for utilizing this anesthetic technique in this patient population.  The use of regional 
analgesia in breast cancer surgery is widely accepted in the anesthesia community as an 
appropriate choice for pain management.  Propofol sedation is also universally accepted as an 
appropriate anesthetic choice.  Therefore, in the development of an optimal anesthesia plan for 
breast cancer surgery, the anesthetist should weigh the potential costs and benefits of their 
anesthetic agents of choice.   
There is an argument to be made that there is an increased risk of potential complications 
using a regional analgesia technique.  Depending on the regional anesthetic technique utilized, 
complications from regional anesthesia used in breast cancer surgery can include injuries such as 
nerve damage, pneumothorax, or seizures and mortality in cases of local anesthetic toxicity 
(Macres, Moore, & Fishman, 2013).  While these risks are a factor to be considered when using 
regional anesthesia, the risks are very low when administered by a skilled anesthetist (Macres et 
al., 2013).  In comparison, the potential long-term benefit to the patient, reducing cancer 
recurrence and increasing survival, would seem to indicate an acceptance of the risks inherent to 
the use of regional analgesia.   
When considering the choice of anesthetic agent, there are small differences in the risks 
to patients in choosing Propofol over Sevoflurane.  One potential difference between anesthetic 
agents used in these surgical procedures is an increased risk of intra-operative awareness when 
using Propofol.  Currently, there is no device utilized in the United States that allows for a 
reliable measure of adequate Propofol serum concentrations to ensure adequate sedation for 
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surgery.  The best measure of adequate sedation when using Propofol is vigilant clinical 
monitoring by the anesthetist.  In addition, there are brain-monitoring devices available that can 
be utilized to gauge overall sedation, but these do not provide a guarantee measure of depth of 
sedation.  Regardless of the differences in overall risk profiles, the potential benefit to the patient 
in reducing postoperative morbidity and mortality seems to outweigh the potential risk of 
Propofol as the anesthetic choice. 
The most important consideration in creating an anesthetic plan should always be focused 
on providing a safe and effective anesthetic.  In the case for using regional analgesia and 
Propofol sedation in breast cancer surgery, the technique is both safe and effective for providing 
adequate analgesia and sedation.  In addition, the evidence supports the potential long-term 
benefit for this anesthetic technique for breast cancer patients.  By avoiding opioids and 
inhalation agents, anesthetists have the potential to significantly improve the surgical outcomes 
in this patient population.  Until there is conclusive evidence that the use of regional anesthesia 
results in poorer patient outcomes in breast cancer surgery, it seems logical to err on the side of 
caution and utilize this technique whenever it is a reasonable choice. 
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